Champions Oncology, Inc. (CSBR) |
|
7.48 0.1 (1.36%)
|
05-16 00:56 |
|
Open: |
7.37 |
Pre. Close: |
7.38 |
|
High:
|
7.53 |
Low:
|
7.37 |
|
Volume:
|
1,967 |
Market Cap:
|
101(M) |
|
|
|
|
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.54 - 7.57 |
7.57 - 7.6 |
|
Low:
|
7.29 - 7.33 |
7.33 - 7.36 |
|
Close:
|
7.43 - 7.48 |
7.48 - 7.53 |
|
Technical analysis |
as of: 2022-05-13 4:37:18 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 9.01 One year: 9.64 |
| Support: |
Support1: 6.84 Support2: 5.69 |
| Resistance: |
Resistance1: 7.71 Resistance2: 8.26 |
| Pivot: |
7.51  |
| Moving Average: |
MA(5): 7.31  MA(20): 7.64
MA(100): 7.95 MA(250): 9.02 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 47.9 %D(3): 37.9 |
| RSI: |
RSI(14): 43.5 |
| 52-week: |
High: 11.25 Low: 6.84 |
| Average Vol(K): |
3-Month: 6 (K) 10-Days: 5 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CSBR ] has closed above bottom band by 46.3%. Bollinger Bands are 12.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sun, 08 May 2022
Bhandup STP bid 54% below estimate, BMC to go to South Korea to verify tech - Times of India
Tue, 03 May 2022
Champions Oncology Announces its Lumin Bioinformatics Platform Selected as a Finalist for the 'Best in Show' Competition at Bio-IT World Conference & Expo - Yahoo Finance
Fri, 29 Apr 2022
Community: LSU announces Tiger 12 Senior Class of 2022 - The Advocate
Tue, 15 Feb 2022
Champions Oncology Announces a Partnership with GigaMune to Discover Novel Tumor-Reactive T Cell Receptors - Yahoo Finance
Thu, 20 Jan 2022
Champions Oncology Announces a Partnership with Fannin Innovation to Jointly Develop Therapeutic Raptamer Drug Conjugates - BioSpace
Fri, 03 Dec 2021
What kind of year did national markets close in terms of competition, how did GVH see 2021? - BBJ - Budapest Business Journal
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
14 (M) |
|
% Held by Insiders
|
5.48e+006 (%) |
|
% Held by Institutions
|
29.2 (%) |
|
Shares Short
|
67 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0.01 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
203 |
|
Profit Margin (%)
|
0.8 |
|
Operating Margin (%)
|
0.9 |
|
Return on Assets (ttm)
|
0.9 |
|
Return on Equity (ttm)
|
5.2 |
|
Qtrly Rev. Growth
|
16.5 |
|
Gross Profit (p.s.)
|
1.9396e+007 |
|
Sales Per Share
|
4.39703e+007 |
|
EBITDA (p.s.)
|
1.67327e+006 |
|
Qtrly Earnings Growth
|
30 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
374 |
|
PEG Ratio
|
8.9 |
|
Price to Book value
|
0.03 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
12.59 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
66940 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
